Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial

Journal:

The Lancet Oncology

Published:

2025-07-17

DOI:

10.1016/s1470-2045(25)00330-4

Affiliations:

38

Authors:

42

Go to article

Institutions	Authors	Share
GlaxoSmithKline USA, United States of America (USA)	9.000000	0.22
GSK, United Kingdom (UK)	3.000000	0.07
Independent Public Clinical Hospital No. 4 in Lublin, Poland	2.000000	0.05
Catalan Institute of Oncology (ICO), Spain	1.333333	0.03
Medical University of Lodz (MUL), Poland	1.000000	0.02
Institute of Cancer of São Paulo (ICESP), Brazil	1.000000	0.02
Botkin Municipal Clinic, Russia	1.000000	0.02
Cross Cancer Institute, AHS, Canada	1.000000	0.02
Clínica São Germano, Brazil	1.000000	0.02
Royal Prince Alfred Hospital (RPAH), USYD, Australia	1.000000	0.02
University of Bologna (UNIBO), Italy	1.000000	0.02
Hadassah Medical Center, HUJI, Israel	1.000000	0.02
Royal North Shore Hospital (RNSH), Australia	1.000000	0.02
The First Affiliated Hospital of Soochow University, China	1.000000	0.02
Medical University of Silesia (SUM), Poland	1.000000	0.02
IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Italy	1.000000	0.02
KU Cancer Center, United States of America (USA)	1.000000	0.02
Samsung Medical Center (SMC), South Korea	1.000000	0.02
University Hospitals of Leicester NHS Trust (UHL), United Kingdom (UK)	1.000000	0.02
Matsuyama Red Cross Hospital, Japan	1.000000	0.02
Pindara Private Hospital, Australia	1.000000	0.02
Rocky Mountain Cancer Centers, The US Oncology Network, United States of America (USA)	1.000000	0.02
Liverpool Hospital, Australia	1.000000	0.02
Christchurch Hospital, New Zealand	1.000000	0.02
University Hospital Ostrava, OSU, Czech Republic	1.000000	0.02
GlaxoSmithKline Canada, Canada	1.000000	0.02
National and Kapodistrian University of Athens (UOA), Greece	0.500000	0.01
University of the Region of Joinville (UNIVILLE), Brazil	0.500000	0.01
Centro de Hematologia e Oncologia, Brazil	0.500000	0.01
Institute of Biomedical Research of Salamanca (IBSAL), Spain	0.500000	0.01
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain	0.500000	0.01
Korea University, South Korea	0.500000	0.01
Josep Carreras Leukaemia Research Institute (IJC), Spain	0.333333	0.01
Germans Trias i Pujol University Hospital (HUGTP), ICS, Spain	0.333333	0.01

Interested in Oncology and Carcinogenesis?